Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Progressing tumors in man and mouse are often infiltrated by dendritic cells (DCs). Deficient antitumor immunity could be related to a lack of tumor-associated antigen (TAA) presentation by tumor-infiltrating DCs (TIDCs) or to a functional defect of TIDCs. Here we investigated the phenotype and function of TIDCs in transplantable and transgenic mouse tumor models. Although TIDCs could encompass various known DC subsets, most had an immature phenotype. We observed that TIDCs were able to present TAA in the context of major histocompatibility complex class I but that they were refractory to stimulation with the combination of lipopolysaccharide, interferon gamma, and anti-CD40 antibody. We could revert TIDC paralysis, however, by in vitro or in vivo stimulation with the combination of a CpG immunostimulatory sequence and an anti-interleukin 10 receptor (IL-10R) antibody. CpG or anti-IL-10R alone were inactive in TIDCs, whereas CpG triggered activation in normal DCs. In particular, CpG plus anti-IL-10R enhanced the TAA-specific immune response and triggered de novo IL-12 production. Subsequently, CpG plus anti-IL-10R treatment showed robust antitumor therapeutic activity exceeding by far that of CpG alone, and elicited antitumor immune memory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The therapeutic effect resulting from enhanced tumor-infiltrating DCs and macrophage infiltrate switching from M2 to M1 consequently produce increased IL-12 and tumor necrosis factor (TNF) (76).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intratumor injections of TLR9 ligand CpG and anti-IL10R antibody are able to reinforce antitumor efficacy in C26 and B16 animal models.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [76]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336 · cited 2×
“Although the main function of dendritic cells (DCs) * is probably to orchestrate a defense against pathogens, DCs are also well equipped to initiate antitumor responses (1).”
BackgroundA Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 1×
“We tested different combinations of substances with the aim of relieving tumor-mediated inhibition and simultaneously mediating DC activation, including combinations of the TLR-9 ligand CpG 1668 (21) and an anti–IL-10R blocking antibody (15).”
MethodMouse and human dendritic cell subtypes
Shortman, K., & Liu, Y.-J. (2002) · Nature Reviews Immunology · doi:10.1038/nri746 · Cited by 2,291 · cited 4×
“In contrast, TIDCs from X/myc hepatocarcinoma were representative of distinct subsets of mouse DCs (19).”
BackgroundResultInfluentialKadowaki, N., Ho, S., Antonenko, S., de Waal Malefyt, R., Kastelein, R. A., Bazan, F., & Liu, Y.-J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.863 · Cited by 1,964 · cited 2×
“Furthermore, it will be of important to test whether our observations also apply to human tumor-infiltrating DCs. Interestingly, a population of plasmacytoid DC precursors has recently been described in human ovarian cancer (27) and these cells, in normal individuals, express TLR9 and respond to selected CpGs (28).”
BackgroundDhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C., & Bhardwaj, N. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.233 · Cited by 1,359 · cited 1×
“Indeed, it was recently reported that immature DC injection would induce antigen-specific T cell unresponsiveness in man (22).”
BackgroundMayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Martin Kast, W., Deleo, A. B., et al. (1995) · Nature Medicine · doi:10.1038/nm1295-1297 · Cited by 1,074
Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology
Asselin-Paturel, C., Boonstra, A., Dalod, M., Durand, I., Yessaad, N., Dezutter-Dambuyant, C., Vicari, A., O'Garra, A., Biron, C., Brière, F., et al. (2001) · Nature Immunology · doi:10.1038/ni736 · Cited by 1,022 · cited 1×
“On the other hand, TIDCs isolated from liver hepatocarcinoma were more diverse, including CD11b and CD11b DCs as well as cells expressing CD8 an/or B220, the latter marker being ascribed to mouse type I IFN-producing cells (19, 20).”
BackgroundSelf-citationZou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Wei, S., Krzysiek, R., Durand-Gasselin, I., Gordon, A., et al. (2001) · Nature Medicine · doi:10.1038/nm1201-1339 · Cited by 653 · cited 1×
“Interestingly, a population of plasmacytoid DC precursors has recently been described in human ovarian cancer (27) and these cells, in normal individuals, express TLR9 and respond to selected CpGs (28).”
BackgroundBell, D., Chomarat, P., Broyles, D., Netto, G., Harb, G. M., Lebecque, S., Valladeau, J., Davoust, J., Palucka, K. A., & Banchereau, J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1417 · Cited by 544
Paglia, P., Chiodoni, C., Rodolfo, M., & Colombo, M. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.317 · Cited by 542
Self-citationWeiner, G. J., Liu, H.-M., Wooldridge, J. E., Dahle, C. E., & Krieg, A. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10833 · Cited by 519
Endotoxin-Induced Maturation of MyD88-Deficient Dendritic Cells
Kaisho, T., Takeuchi, O., Kawai, T., Hoshino, K., & Akira, S. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5688 · Cited by 489 · cited 2×
“Furthermore, it will be of important to test whether our observations also apply to human tumor-infiltrating DCs. Interestingly, a population of plasmacytoid DC precursors has recently been described in human ovarian cancer (27) and these cells, in normal individuals, express TLR9 and respond to selected CpGs (28).”
BackgroundSica, A., Saccani, A., Bottazzi, B., Polentarutti, N., Vecchi, A., Van Damme, J., & Mantovani, A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.2.762 · Cited by 426 · cited 1×
“The ability to induce TIDC activation with the combination of anti–IL-10R plus CpG, as well as with an anti–IL10 antibody plus CpG (unpublished data), strongly suggests that IL-10 was one of the factors responsible for the induction of the refractory state in vivo, as already described for tumor-associated macrophages…”
BackgroundHuang, A. Y., Gulden, P. H., Woods, A. S., Thomas, M. C., Tong, C. D., Wang, W., Engelhard, V. H., Pasternack, G., Cotter, R., Hunt, D., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9730 · Cited by 388
Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma
Enk, A. H., Jonuleit, H., Saloga, J., & Knop, J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971104)73:3<309::aid-ijc1>3.0.co;2-3 · Cited by 386
The host—tumor immune conflict: from immunosuppression to resistance and destruction
Chouaib, S., Asselin-Paturel, C., Mami-Chouaib, F., Caignard, A., & Blay, J. Y. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01115-8 · Cited by 350 · cited 1×
“Furthermore, tumor cells or tumor-infiltrating cells may produce IL-10, PGE 2 , and TGF that impair DC functions (11, 12).”
BackgroundDendritic Cells as Sensors of Infection
e Sousa, C. R. (2001) · Immunity · doi:10.1016/s1074-7613(01)00136-4 · Cited by 319
Ronchetti, A., Rovere, P., Iezzi, G., Galati, G., Heltai, S., Protti, M. P., Garancini, M. P., Manfredi, A. A., Rugarli, C., & Bellone, M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.130 · Cited by 293 · cited 1×
“Indeed, in vitro–generated DCs are able to sample and present tumor antigens for the priming of cytotoxic T cells (2) and DCs can produce the cytokines IL-12, TNF , and IFN- that play diverse roles in antitumor immune responses (1).”
BackgroundThe hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice
Terradillos, O., Billet, O., Renard, C.-A., Levy, R., Molina, T., Briand, P., & Buendia, M. A. (1997) · Oncogene · doi:10.1038/sj.onc.1200850 · Cited by 285 · cited 1×
“hepatocarcinoma developing in X/ myc transgenic mice (13) and analyzed their phenotype (Fig.”
BackgroundDivergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides with Distinct CpG Motifs
Ballas, Z. K., Krieg, A. M., Warren, T., Rasmussen, W., Davis, H. L., Waldschmidt, M., & Weiner, G. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.9.4878 · Cited by 252 · cited 1×
“Repeated high-dose peritumoral or intraperitoneal injection of CpG could also lead to tumor rejection in the B16 model (32, 33).”
BackgroundTumour escape from immune surveillance through dendritic cell inactivation
Vicari, A. P., Caux, C., & Trinchieri, G. (2002) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0400 · Cited by 228 · cited 1×
“Furthermore, tumor cells or tumor-infiltrating cells may produce IL-10, PGE 2 , and TGF that impair DC functions (11, 12).”
BackgroundSelf-citationKawarada, Y., Ganss, R., Garbi, N., Sacher, T., Arnold, B., & Hämmerling, G. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.9.5247 · Cited by 220 · cited 1×
“Repeated high-dose peritumoral or intraperitoneal injection of CpG could also lead to tumor rejection in the B16 model (32, 33).”
BackgroundSeo, N., Hayakawa, S., Takigawa, M., & Tokura, Y. (2001) · Immunology · doi:10.1046/j.1365-2567.2001.01279.x · Cited by 206 · cited 1×
“It was also shown that IL-10 expressed within tumors could promote the generation of tolerogenic regulatory T cells (23).”
BackgroundHung, A. C. F. (1996) · Medical Entomology and Zoology · Cited by 206
Brunner, C., Seiderer, J., Schlamp, A., Bidlingmaier, M., Eigler, A., Haimerl, W., Lehr, H.-A., Krieg, A. M., Hartmann, G., & Endres, S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6278 · Cited by 192
Chiodoni, C., Paglia, P., Stoppacciaro, A., Rodolfo, M., Parenza, M., & Colombo, M. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.1.125 · Cited by 175 · cited 3×
“5 B) as reported previously for C26-GMCD40L tumors (9).”
BackgroundMethodSelf-citationAllione, A., Consalvo, M., Nanni, P., Lollini, P., Cavallo, F., Giovarelli, M., Forni, M., Gulino, A., Colombo, M. P., & Dellabona, P. (1994) · PubMed · Cited by 162
Self-citationAntitumor Effects of the Mouse Chemokine 6Ckine/SLC Through Angiostatic and Immunological Mechanisms
Vicari, A. P., Ait-Yahia, S., Chemin, K., Mueller, A., Zlotnik, A., & Caux, C. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.4.1992 · Cited by 153 · cited 3×
“TIDCs purified from a subcutaneously implanted C26 colon carcinoma transduced with the 6Ckine chemokine (14) were CD11b , CD8 , and B220 in their vast majority (Fig.”
BackgroundMethodSelf-citationPapillary Carcinoma of the Thyroid
Scarpino, S., Stoppacciaro, A., Ballerini, F., Marchesi, M., Prat, M., Stella, M. C., Sozzani, S., Allavena, P., Mantovani, A., & Ruco, L. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64951-6 · Cited by 135
The dendritic cell and human cancer vaccines
Dallal, R. M., & Lotze, M. T. (2000) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00146-1 · Cited by 129 · cited 1×
“Today, this strategy is being evaluated in clinical trials investigating what is the most efficient subset of DCs, form of antigen, and activation stimulus (5).”
In vivo manipulation of dendritic cells to induce therapeutic immunity
Merad, M., Sugie, T., Engleman, E. G., & Fong, L. (2002) · Blood · doi:10.1182/blood.v99.5.1676 · Cited by 109
Sweet, M. J., Campbell, C. C., Sester, D. P., Xu, D., McDonald, R. C., Stacey, K. J., Hume, D. A., & Liew, F. Y. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.1.392 · Cited by 98
Sijts, A. J. A. M., OSSENDORP, F. A., Mengedé, E., van den Elsen, P. J., & Melief, C. J. M. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.1.106 · Cited by 60 · cited 3×
“The MC38 (H-2b) colon carcinoma expresses the same TAA and contains a Kb-restricted peptide recognized by the TG905 CTL line (17).”
BackgroundMethodCastro, A. G., Neighbors, M., Hurst, S. D., Zonin, F., Silva, R. A., Murphy, E., Liu, Y.-J., & O'Garra, A. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.10.1529 · Cited by 57 · cited 3×
“Therefore, as already shown by our previous report (15), it seems that anti–IL-10R antibody can strongly potentiate a microbial stimulus, in particular mediated through a Toll-like receptor.”
BackgroundMethodSelf-citationInterferon with dendritic cells?
Tough, D. F., & Kamath, A. T. (2001) · Nature Immunology · doi:10.1038/ni1201-1098 · Cited by 8
Cited by
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
“Inhibition of IL-10 with an anti-IL-10 receptor antibody combined with CpG-ODN activation was shown to reverse the tolerogenic state of tumor-infiltrating DCs and to augment their therapeutic efficacy in a mouse tumor model (269).”
BackgroundCommensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251
Self-citationCrosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
“For example, blocking IL-10-receptor signalling, which probably involves inhibition of STAT3 activity, can markedly enhance CpG-oligodeoxynucleotide-induced anti-tumour immunit”
Smoldering and polarized inflammation in the initiation and promotion of malignant disease
Balkwill, F., Charles, K. A., & Mantovani, A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.013 · Cited by 1,769
Metadata
- Authors
- Vicari, A. P., Chiodoni, C., Vaure, C., Aït-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., O'Garra, A., Trinchieri, G., & Caux, C.
- Affiliations
- 1Schering-Plough Laboratory for Immunological Research, 69571 Dardilly, France
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Inserm (FR)
- 4DNAX Research Institute, Palo Alto, CA 94304
- ORCID
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2002-08-19
- Volume
- 196
- Issue
- 4
- Pages
- 541-549
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2196048
- OpenAlex
- W2156592930
- Cited by
- 343
- References
- 35
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 10 · 2021: 8 · 2020: 8 · 2019: 14 · 2018: 7 · 2017: 19 · 2016: 12 · 2015: 17 · 2014: 21 · 2013: 21 · 2012: 21
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor-infiltrating dendritic cells, MHC class I, DC maturation, IL-12, antitumor immunity, antitumor immune memory, transplantable tumors
- MeSH terms
- Adjuvants, Immunologic, Animals, Antibodies, Monoclonal, Dendritic Cells, Female, Immunity, Active, Immunity, Innate, Immunologic Memory, Interferon-gamma, Killer Cells, Natural, Lipopolysaccharides, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Oligodeoxyribonucleotides, Tumor Cells, Cultured, Antigens, Tumor-Associated, Carbohydrate, Mice, SCID, Receptors, Interleukin, CD8-Positive T-Lymphocytes, CpG Islands, CD40 Antigens, Mice, Receptors, Interleukin-10
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.